BD SurePath TM Direct to Slide introduced today
Chennai, June 27, 2018: BD Life Sciences-Diagnostic Systems, a segment of BD
(Becton, Dickinson and Company), a leading global medical technology company, today
announced the launch of BD SurePath TM Direct to Slide. It is a Liquid Based Cytology
(LBC) test intended to be used for screening and detection of cervical cancer, pre-
cancerous lesions, atypical cells and all other cytologic categories. Offering a complete
LBC solution and characterized by FDA standardized sample collection process, through
ease of use, 100% of the collected sample is sent to the lab. Utilizing BD’s proprietary
cell enrichment technique, BD SurePath™ Direct to Slide improved slide quality, whilst
accommodating the requirements of labs with lower volume testing. BD SurePath TM
Direct to Slide is a unique LBC technique that will offer availability of residual sample for
conducting important additional follow up tests without the need for repeat sampling. A
scientific session with city’s leading Obstetricians /Gynecologist surgeons and
pathologists was inaugurated at the campus by Smt Bharathi Reddy, Trustee & CEO
Vijaya Group of Hospitals.
Traditionally, conventional pap smear, a simple and quick test has been the mainstay for
cervical cancer screening. However, this method has limitations in preparation technique
and its ability to detect every abnormality, hence the need to move towards a better and
efficient technique. As innovation and research continues in battling the increasing
burden of cervical cancer, new technologies such as Liquid Based Cytology (LBC) have
emerged as superior screening methods.
Commenting that cervical cancer can be prevented by screening women systematically
through organized population based programmes,Dr. A. Tamilselvi, Consultant
Urogynaecologist & Obstetrician, Madras Medical Mission Hospital & Mangai
Women’s Health Exclusive, Chennai said, “Liquid Based Cytology is a cervical cancer
screening technique which ensures the early detection of precancerous changes of the
cervix. This allows timely treatment of the changes and helps in prevention of cervical
cancer. This technique is an advanced method of cervical cancer screening which
enhances the chances of satisfactory smears, allows better clarity and lesser time in
smear interpretation. It is an important step in prevention of cervical cancer and
reduction of deaths due to the disease. We as healthcare professionals, are striving to
ensure that an increasing number of women undergo screening tests so that the disease
is diagnosed at the earliest.”
Pavan Mocherla, Managing Director, BD–India added, “Early detection of cervical
cancer and its malignant precursors is imperative for survival. BD’s cancer diagnostic
capabilities focus on improving health outcomes for patients by providing laboratories
with solutions that improve quality, enhance laboratory system productivity and inform
medical decisions. In India where women’s health is a priority, we are glad that BD
SurePath TM Direct to Slide will be able to enhance the standard of patient care,
representing the next milestone in cervical cancer screening.”
Cervical cancer is the second most common cancer in the country among women aged
between 15 and 44 years. The importance of proactive and periodic screening stems
from the fact that cervical cancer is a preventable and curable condition if detected in
the asymptomatic stages. Unfortunately, in India there continues to be a major gap in
the awareness levels in women regarding screening especially while still asymptomatic.
This further results in delayed diagnosis when the cost of the treatment becomes exorbitant.
Hence it is critical to understand the advantages of screening and opt for appropriate testing methods.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.